What the research found

Visceral fat—the metabolically active tissue surrounding organs—shows consistent associations with insulin resistance, elevated triglycerides, and lower HDL cholesterol across populations. A one standard deviation increase in visceral adipose tissue correlates with hepatic insulin resistance increases of 14–28%, triglyceride rises of 8–16%, and HDL reductions of 1.0–0.05 mmol/L, independent of overall body mass.

Importantly, these metabolic consequences differ by ancestry. African and African-descended populations show lower visceral and subcutaneous fat levels relative to their BMI and waist circumference compared to European populations—yet they experience disproportionately high rates of insulin resistance and type 2 diabetes. This suggests subcutaneous fat distribution, particularly in deeper layers, may carry different metabolic risk in these groups than previously recognised. The deeper subcutaneous fat layers appear to correlate with metabolic syndrome risk similarly to visceral fat itself.

Why it matters for you

If you're using anabolics or growth hormone, visceral fat reduction is often a stated goal—but the cardiometabolic penalty matters more than the aesthetic one. Visceral fat drives insulin resistance and lipid dysfunction even when total body fat appears reasonable, so tracking fasting insulin, triglycerides, and HDL becomes especially important during enhanced protocols. These biomarkers are more sensitive indicators of visceral accumulation than scale weight or waist circumference alone.

Your ancestry also influences how your body distributes fat and metabolises it. If you have African ancestry, subcutaneous fat—particularly abdominal subcutaneous deposits—may confer greater insulin resistance risk than the same amount of visceral fat would in someone of European ancestry. This means ethnicity-blind body composition targets may not apply equally; your blood lipids and glucose tolerance during a cycle or TRT protocol are better guides than waist circumference alone.

Caveats

• Observational and cross-sectional; causality between fat depots and metabolic dysfunction not definitively established
• Ancestry classifications are population-level trends with substantial individual variation
• The article covers correlations but does not report effect sizes for specific anabolic agents on visceral fat reduction
• Mechanistic explanations for subcutaneous fat differences between populations remain speculative